# EDGAR Filing Document

**Accession Number:** 0000943819
**File Stem:** 0001193125-25-289878
**Filing Date:** 2025-11
**Character Count:** 10973
**Document Hash:** 1ee355a10b9b3840f5c60e9d13a2f546
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-289878.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001193125-25-289878

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251119

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RESMED INC
- **CENTRAL INDEX KEY:** 0000943819
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980152841
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15317
- **FILM NUMBER:** 251503457

**BUSINESS ADDRESS:**
- **STREET 1:** 9001 SPECTRUM CENTER BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92123
- **BUSINESS PHONE:** 8587462400

**MAIL ADDRESS:**
- **STREET 1:** 9001 SPECTRUM CENTER BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92123

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### November 19, 2025

#### Date of Report (Date of earliest event reported)

## ResMed Inc.

#### (Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15317** | **98-0152841** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### 9001 Spectrum Center Boulevard

#### San Diego, California 92123

#### (Address of Principal Executive Offices) (Zip Code)
(858) 836-5000

#### (Registrant's telephone number, including area code)

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.004 par value | RMD | NYSE |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

Richard Sulpizio did not seek re-election at the Annual Meeting (as defined below); his term expired on November 19, 2025 at the conclusion of the Annual Meeting, creating a vacancy on our board of directors. On November 19, 2025, our board of directors approved reducing the number of directors serving on our board from twelve (12) to eleven (11).

#### ResMed Inc. 2009 Incentive Award Plan
On November 19, 2025, at the 2025 annual meeting of stockholders of ResMed Inc. (the "Annual Meeting"), our stockholders approved an amendment and restatement (the "2009 Plan Amendment") of the ResMed Inc. 2009 Incentive Award Plan, as Amended and Restated (the "2009 Plan") and as noted in Item 5.07 below. The 2009 Plan Amendment (i) increases the number of shares of common stock reserved for issuance under the 2009 Plan by 2,400,000 shares, (ii) eliminates the fixed term of the 2009 Plan, and (iii) authorizes the grant of incentive stock options under the 2009 Plan. On August 15, 2025, based on the recommendation of the compensation and leadership committee (the "CLDC"), our board adopted the 2009 Plan Amendment, subject to stockholder approval. The 2009 Plan Amendment became effective upon stockholder approval at the Annual Meeting. A detailed summary of the 2009 Plan Amendment is set forth in our Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on October 2, 2025 (the "Proxy Statement") under the caption "Proposal 4 Approval of the Amendment and Restatement of the ResMed Inc. 2009 Incentive Award Plan, Including Increase of Reserved Shares and Elimination of Fixed Term," which summary is incorporated herein by reference. Such summary and the foregoing description of the 2009 Plan Amendment are qualified in their entirety by reference to the full text of the 2009 Plan Amendment, which is filed hereto as Exhibit 10.1 and incorporated herein by reference.

#### ResMed Inc. 2018 Employee Stock Purchase Plan
At the Annual Meeting, our stockholders also approved an amendment and restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan (the "ESPP Amendment"). The ESPP Amendment (i) increases the number of shares of our common stock that may be issued or transferred by awards under the ESPP Amendment by 3,000,000 shares, (ii) eliminates the fixed term of the ESPP Amendment; and (iii) provides for the grant of options (or rights) to purchase shares of our common stock that are intended to be tax qualified under Section 423 of the Code. On August 15, 2025, based on the recommendation of the CLDC, our board adopted the ESPP Amendment, subject to stockholder approval. The ESPP Amendment became effective upon stockholder approval at the Annual Meeting.

A detailed summary of the ESPP Amendment is set forth in the Proxy Statement under the caption "Proposal 5 Approval of the Amendment and Restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan, Including Increase of Reserved Shares and Elimination of Fixed Term," which summary is incorporated herein by reference. Such summary and the foregoing description of the ESPP Amendment are qualified in their entirety by reference to the full text of the ESPP Amendment, which is filed hereto as Exhibit 10.2 and incorporated herein by reference.

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

On November 19, 2025, at the Annual Meeting, our stockholders (1) elected the eleven nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2026; (3) approved, on an advisory basis, the compensation of our named executive officers ("say-on-pay"); (4) approved the 2009 Plan Amendment; and (5) approved the ESPP Amendment.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For** | **Against** | **Abstain** | **Broker<br>Non-Votes** |
|  Item of business 1: Elect the following eleven directors, each to serve until our 2026 annual meeting and until their successors are elected and qualified: |  |  |  |  |
|  Carol Burt | 98942083 | 10615305 | 119685 | 4752219 |
|  Jan De Witte | 108689704 | 852841 | 134528 | 4752219 |
|  Christopher DelOrefice | 107639634 | 1901580 | 135859 | 4752219 |
|  Karen Drexler | 105376639 | 4156115 | 144319 | 4752219 |
|  Michael Farrell | 103568951 | 5608816 | 499306 | 4752219 |
|  Peter Farrell | 107881784 | 1482898 | 312391 | 4752219 |
|  Harjit Gill | 108539891 | 1001072 | 136110 | 4752219 |
|  John Hernandez | 108694559 | 843100 | 139414 | 4752219 |
|  Nicole Mowad-Nassar | 109403870 | 135377 | 137826 | 4752219 |
|  Desney Tan | 107409134 | 2119305 | 148634 | 4752219 |
|  Ronald Taylor | 103178181 | 6360604 | 138288 | 4752219 |
|  | **For** | **Against** | **Abstain** | **Broker<br>Non-Votes** |
|  Item of business 2: Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2026. | 103397962 | 10908581 | 122749 |  |
|  | **For** | **Against** | **Abstain** | **Broker<br>Non-Votes** |
|  Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement ("say-on-pay"). | 98435762 | 11004916 | 236395 | 4752219 |
|  | **For** | **Against** | **Abstain** | **Broker<br>Non-Votes** |
|  Item of business 4: Approve the amendment and restatement of the ResMed Inc. 2009 Incentive Award Plan | 104708816 | 4739662 | 228595 | 4752219 |
|  | **For** | **Against** | **Abstain** | **Broker<br>Non-Votes** |
|  Item of business 5: Approve the amendment and restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan | 109320625 | 246682 | 109766 | 4752219 |

---

------

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| Exhibits: | Description of Document |
| 10.1 | [The ResMed Inc. 2009 Incentive Award Plan, as amended and restated (incorporated by reference to Appendix A of ResMed Inc.'s Definitive Proxy Statement filed October 2, 2025).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/943819/000094381925000079/rmd-20251001.htm#i364d366cdbe14ca6973f2fdfeb67a3cd_1359) |
| 10.2 | [The ResMed Inc. 2018 Employee Stock Purchase Plan, as amended and restated (incorporated by reference to Appendix B of ResMed Inc.'s Definitive Proxy Statement filed on October 2, 2025).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/943819/000094381925000079/rmd-20251001.htm#i364d366cdbe14ca6973f2fdfeb67a3cd_1410) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL, document). |

---

------

#### SIGNATURES
We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

---

| | | |
|:---|:---|:---|
|  | **RESMED INC.** | **RESMED INC.** |
| Date: November 20, 2025 | By: | /s/ Michael Rider |
|  |  | Michael Rider |
|  |  | Chief Legal Officer, Global General Counsel and Secretary |

---